cyrilzakka/clinical-trials huggingface dataset:
Artificial Intelligence in Children's Clinic

In China, the number of children's medical services is still far behind the growing demand for children's health care. The phenomenon of children's parents queuing overnight for registration is no longer surprising. This is because of the increase in the number of children and the shortage of pediatric talents. In the department of pediatrics, the number of patients increases year by year, but pediatrician is short of supply from beginning to end. In addition to outpatient service, pediatricians in large hospitals also perform operations, scientific research and other tasks. As a result, many doctors have to give up their vacations, which makes them miserable and reduces their enthusiasm for work. The long queuing time also reduced the satisfaction of patients, resulting in the intensification of the conflict between pediatric doctors and patients.

This research project aims to create a human-computer integrated system and develop a new diagnosis process embedded with artificial intelligence (AI). The function of AI system mainly includes 3 aspects. (1) The patient uses a mobile phone application embedded with AI that allows him to have check-up before see a doctor. The program will ask the patient a number of questions. Then, based on the patient's answers, AI will recommend a series of examination, all of which would be reviewed by the physician beforehand. After the patient pays for it, he could go straight to do the examination. So, next he could go to the doctor with the examination report which saves the patient the trouble of queuing. (2) At the same time, the AI system could also automate the medical history. The patient would complete self-help history collection in the spare time. The AI system collects the medical history and automatically import it to the doctor's computer. Doctors' main job is to modify the medical history generated by AI. To some extent, it lightens the burden of doctors. (3) During the visit, the AI system automatically captures the information in the patient's electronic medical record and generates the possible diagnosis. This process is of great help to junior doctors, and may serve as a cue.

In short, this study is helpful to effectively reduce the waiting time of patients and greatly increase their medical experience. While reducing the work intensity of doctors, the outpatient procedure of our hospital has been effectively optimized to alleviate the shortage of pediatricians to some extent.

Relying on mobile application and computer software, it would achieve:

1. Intelligent guidance and matching the department;
2. Intelligent medical history collection, and AI medical record generation;
3. Automatically recommend examination items;
4. Assist in clinical diagnosis and make intelligent diagnosis suggestion.

Eligibility Criteria:
Inclusion Criteria:

Patients aged 2 months to 18 years old and will go to Shanghai children's medical center for treatment.

Exclusion Criteria:

1. People who don't agree to participate.
2. People who can't cooperate.
3. People who are difficult to follow up.
Clinical Outcomes for Offering Genetic Testing in a Tiered Approach

This clinical quality improvement study reviews and develops a clinical operations workflow to identify cancer patients who meet criteria for genetic counseling and testing. This study may improve utilization of genetic counseling and testing amongst community-based oncology providers caring for cancer patients in a rural and underserved area.

OUTLINE: Medical oncologists at Olympic Medical Center (OMC) participated in this study and received a peer coaching intervention during phase II to help identify patients who meet criteria for genetic counseling and testing

PHASE I: Patients' medical data are collected; no intervention.

PHASE II: Olympic Medical Center (OMC) patients complete family history questionnaires and their medical data are collected. Seattle Cancer Care Alliance (SCCA) subject matter experts and OMC providers review patients' medical data at bi-weekly virtual conferences. OMC providers will be consenting to release their patients' medical records to SCCA so that SCCA subject matter experts (cancer geneticist and/or genetic counselor) can identify patients with an underlying hereditary cancer syndrome to be offered genetic counseling and testing.

OMC providers receive coaching from SCCA subject matter experts for guidance on providing genetic counseling and testing to their patients.

Eligibility Criteria:
Inclusion Criteria:

* Medical oncology providers at OMC who see patients with an active diagnosis of breast, ovarian, prostate, colon, or pancreatic cancer

Exclusion Criteria:

* OMC providers who do not see patients with an active diagnosis of cancer
* OMC providers who see patients who are minors
* OMC providers who see patients with precancerous lesions such as ductal carcinoma in situ (the presence of abnormal cells inside a milk duct in the breast) or colon polyps (a small clump of cells that form on the lining of the colon or rectum)
A Phase 1 Study Comparing AVP-786 With AVP-923

To compare pharmacokinetics (PK) of AVP-786 (deuterated \[d6\] dextromethorphan hydrobromide \[d6-DM\]/quinidine sulfate \[Q\]) to AVP-923 (dextromethorphan hydrobromide \[DM\]/Q) at steady state.


Eligibility Criteria:
Inclusion Criteria:

* Healthy adult males or females
* 18 - 60 years of age
* BMI 18 - 32 kg/m2

Exclusion Criteria:

* History or presence of significant disease
* History of substance abuse and/or alcohol abuse with the past 2 years
* Use of tobacco-containing or nicotine-containing products within 6 months
* Use of any prescription or the over-the-counter medications within 14 days
Secondary Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancers

This novel study was specifically designed for platinum resistant recurrent ovarian cancers and aimed to compare cases who received secondary cytoreductive surgery for isolated recurrence and chemotherapy versus chemotherapy alone. This comparison will conduct the intraoperative events, postoperative morbidity and mortality, pathological outcomes and long-term oncological outcomes as regarding progression free survival and overall survival rates.

Baseline postoperative imaging with the use of abdominopelvic CT or MRI was to be completed during a 28-day window in which chemotherapy was initiated. Disease is also assessed after cycles 3 and 6 of trial treatment (and after cycle 8, if administered), every 3 months for 2 years, and then every 6 months thereafter. Physical examinations will be performed, and serum CA-125 levels measured at the beginning of each cycle of chemotherapy. Treatment-free interval (6 to 12 months or \>12 months after the last chemotherapy infusion) will be reported.

Eligibility Criteria:
Inclusion Criteria:

* platinum-resistant, recurrent epithelial ovarian cancer
* amenable to complete gross resection, isolated recurrence
* adequate renal, hepatic, and bone marrow function,
* performance-status ECOG score of 0 to 2.

Exclusion Criteria:

* not medically fit for surgery
* diffuse carcinomatosis, ascites, or extra-abdominal disease
Fluorescein vs. iMRI in Resection of Malignant High Grade Glioma

This study plans to learn more about if fluorescein with intraoperative Magnetic Resonance Imaging (MRI) is as good as intraoperative MRI (iMRI) alone in detecting the presence of tumor tissue during surgery.

Both fluorescein and intraoperative MRI have been studied and routinely used to aid the neurosurgeon in distinguishing normal brain from tumor, helping the neurosurgeon to safely resect more tumor tissue during surgery.

This study will enroll patients with malignant high grade glioma who are going to have a surgery to remove their brain tumor.

For half of the patients, fluorescein and intraoperative MRI will be used together during surgery. For half of the patients, only intraoperative MRI will be used during surgery. iMRI is used as final verification of complete, safe resection in both arms.

Extent of surgical resection of malignant high grade glioma has been established as one of the most important predictors of overall survival and six-month progression free survival. Unfortunately, it is often difficult in surgery to distinguish between tumor and normal brain. Various technologies have been developed to help the surgeon more readily safely increase extent of resection in order to achieve an improved survival after glioblastoma resection. Fluorescein has been used at some institutions for a number of years to improve visualization of high-grade gliomas enabling their better resection. Intraoperative MRI has also been developed with similar intent, allowing the patient to be imaged intraoperatively to determine extent of resection and any need for further resection prior to leaving the operating room. While there is some evidence these technologies improve extent of resection in comparison to historical controls, they have never been tested against each other in any prospective fashion.

Intraoperative MRI has significant cost and significantly increases operative time. Fluorescein is a very inexpensive injectable agent and, if as good at achieving gross total resection as intraoperative MRI, would offer patients similar surgical outcomes with less anesthetic time and cost than intraoperative MRI. This study aims to investigate the value of fluorescein or intraoperative MRI in malignant glioma patients' extent of tumor resection in a prospectively randomized manner.

Eligibility Criteria:
Inclusion Criteria:

* Presents with presumed or pathologically proven enhancing primary or secondary high grade glioma for surgical resection
* Eligible for gross total resection of enhancing component of tumor
* Karnofsy performance status \>/= 70%

Exclusion Criteria:

* Presence of multi-focal disease
* Disease that crosses the mid-line
* History of adverse reaction to flourescein
* Known ongoing pregnancy
* Inability to grant consent
* Contraindication to perform iMRI
* Contraindication to flourescein
An Observational Study to Evaluate Efficacy and Safety of Risperidone Long-Acting Injection for Treatment of Schizophrenia

The purpose of this study is to evaluate the long-term treatment efficacy, and safety of risperidone long-acting injection in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self).

This is an open-label (all people know the identity of the intervention), multi-center (conducted in more than one center), prospective (study following participants forward in time) and observational study of risperidone long-acting injection in participants with schizophrenia. The study consists of 2 parts: Screening (that is, 28 days before study commences on Day 1) and Treatment (that is, Week 1-24). All the eligible participants (after risperidone intolerance test during screening) will be receiving risperidone as intramuscular injection (injection of a substance into a muscle) at a dose of, either 25 milligram (mg), 37.5 mg or 50 mg every two weeks. Efficacy of the participants will be primarily evaluated through Positive and Negative Syndrome Scale. Participants' safety will be monitored throughout the study.

Eligibility Criteria:
Inclusion Criteria:

* Male or female, age 18-65 years
* Participant must meet the diagnostic criteria for schizophrenia or schizophreniform disorder according to Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV)-TM
* Total course of disease no more than 5 years
* According to physician's discretion, participants need to be changed to risperidone long-acting injection and other atypical anti-psychotic drug
* Participant or their legally acceptable representatives must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study

Exclusion Criteria:

* Significant risk of suicidal or violent behavior, as clinically assessed by the Investigator
* Have aggressive behavior and excited , restless
* History or current symptoms of tardive dyskinesia; neuroleptic malignant syndrome; evidence of dysfunction of liver and kidney and other severe physical diseases; and severe, life-threatening allergic reaction to any drug
* Known hypersensitivity to risperidone
* Female participant who is pregnant or breastfeeding or planning to become pregnant during the study period
Safety/Efficacy of Valsartan/Hydrochlorothiazide Combination Compared to Hydrochlorothiazide in Obese Hypertensive Adults

The purpose of this study is to compare the blood pressure lowering efficacy of valsartan/hydrochlorothiazide (HCTZ) compared to hydrochlorothiazide for the treatment of obese hypertensive (mean sitting systolic blood pressure \[MSSBP\] \>150 mmHg) patients.


Eligibility Criteria:
Inclusion Criteria:

* 40 years of age or older
* Moderate or severe high blood pressure defined as systolic blood pressure (the top number) greater than or equal to 150 mmHg and diastolic blood pressure (the bottom number) less then 110 mmHg
* Central (abdominal) obesity

Exclusion Criteria:

* Systolic blood pressure (the top number) greater than or equal to 180 mmHg and diastolic blood pressure (the bottom number) greater than or equal to 110 mmHg
* Currently taking more then 3 medications to treat high blood pressure
* Inability to stop all current blood pressure medications if any up to 4 weeks
* History of Type 1 or Type 2 diabetes
* History of stroke, mini-stroke (transient ischemic attack) or heart attack within the last 6 months
* History of or current diagnosis of congestive heart failure
* History of cancer within the past 5 years with the exception of localized basal cell carcinoma or squamous cell carcinoma
* Women who are pregnant or nursing
* Alcohol or drug abuse within the last 2 years

Other protocol-defined inclusion/exclusion criteria may apply
The NanoStrand Clinical Study

A prospective, multi-center, randomized, self-controlled, single-blinded, clinical study evaluating the NanoMetalene implant as compared to the PEEK and allograft implants in ACDF for the treatment of cervical degenerative disc disease (DDD).

PEEK: Polyetheretherketone ACDF: Anterior cervical discectomy and fusion

Eligibility Criteria:
Inclusion Criteria:

* Cervical degenerative disc disease
* Requires primary spinal fusion from C3-C7
* Minimum of 6 weeks of non-operative treatment
* Signed informed consent form

Exclusion Criteria:

* Uncontrolled type I or II diabetes mellitus
* Morbid obesity
* Documented history of alcohol or drug abuse
* Fever or leukocytosis
* Current systemic infection
* Active malignancy and/or current chemotherapy
* Known history of osteoporosis
* Prior fusion or total disc replacement at the operative level or an adjacent level
* Infection of the operative site
* Use of implants from other systems
* Pregnancy
* Participation in another research study
Treatment of Scars and Dysfunctions of the Pelvic Floor in Postpartum

Recruitment of patients who have suffered third- and fourth-degree perineal tear during childbirth, and who have given birth at the Hospital Universitario Marqués de Valdecilla (Santander, Spain). They are distributed randomly in two groups an experimental group who apply techniques of physiotherapy and a control group, receiving medical treatment.

At the same time is recruited the same number of patients who have not suffered tear and whose birth has been instrumental, dividing into two groups, control and experimental. And the same number of patients who have given birth but have not suffered tear or instrumental delivery, divided also into control group and experimental.


Eligibility Criteria:
Inclusion Criteria:

* Patients who have dysfunctions in the pelvic floor after childbirth
* Patients who have given birth at the Hospital Universitario Marqués de Valdecilla
* Patients who do not have any medical alteration that does not indicate the treatment

Exclusion Criteria:

* Patients who do not have pelvic floor dysfunctions after childbirth
* Patients who have not given birth at the Hospital Universitario Marqués de Valdecilla
* Patients who have any medical changes that counter the treatment
Real World Study on Erlotinib/Gefitinib Combined With Bevacizumab in Advanced Non-aquamous Non-small Cell Lung Cancer

This study aims to explore the efficacy and safety of Erlotinib/Gefitinib combined with bevacizumab in the real world for advanced non-squamous cell lung cancer with EGFR mutation, explore new drug resistance mechanisms under the A+T regimen and consistency between plasma and tissue detection driving genes, and finally assess the predictive value of plasma dynamic detection driving gene mutation profiles in predicting disease. The role of disease progression risk.

A retrospective study of 30 cases of advanced non-squamous non-small cell lung cancer (NSCLC) with EGFR mutation positive treated with A+T was conducted to observe the efficacy and safety of A+T regimen in the real world. Exploratory research contents are as follows: 1. Consistency between tissue gene test (NGS) and plasma gene test (NGS) at the initial diagnosis; 2. Consistency between tissue gene test (NGS) and plasma gene test (NGS) at the progression of A + T treatment; 3. New drug resistance mechanism of A + T treatment; 4. Plasma dynamics during A + T treatment. Detection (the first efficacy evaluation and a blood sampling before imaging PD) exploration and imaging progress sequence; 5. Plasma large panel dynamic drive gene mutation spectrum analysis to build disease progression risk model.

Eligibility Criteria:
Inclusion Criteria:

* EGFR mutation(19del/L858R)
* advanced non-saquamous non-small cell lung cancer
* primary treatment of first diagnosis
* performance status（0-1)

Exclusion Criteria:

* other genes mutation
* saquamous
Postural Assessment by Photogrammetry

This study aimed to measure the degree of thoracic kyphosis in elderly women with those affected by osteoporosis in the spine, through photogrammetry computer and check the difference between the values obtained with the assumption of greater thoracic kyphosis in osteoporotic women.

The decrease in bone density of vertebrae leads to a reduction of the anterior vertebral bodies, resulting in compression and collapse of vertebrae, with narrowing of intervertebral disc spaces and, determining a number of deformities in the spine and postural changes, among which can highlight the increase in thoracic kyphosis. This becomes significantly higher with age and after menopause, defined as an increase in curvature in the sagittal plane of the thoracic spine.

Radiographic images have been used for the measurement of thoracic kyphosis, but with some drawbacks of this method such as radiation exposure, radiographic image quality unsatisfactory hampering its analysis and the lack of equipment in the physical environment to monitor clinical evolution of the treatment, causing thus the search for noninvasive methods for evaluating the curves of the spine, including the photogrammetry computed.

According to the American Society of Photogrammetry, the computed photogrammetry is "the art, science and technology of information on physical objects and environment through processes of recording, measuring and interpreting photographic images and patterns of electromagnetic radiant energy and other sources." It is a widely used tool for assessment by quantifying the postural changes through the application of photogrammetric principles to photographic images obtained in body movements, adding to the diagnostic evaluation for physical therapy in different areas.

Eligibility Criteria:
Inclusion Criteria:

* age between 50 and 80 years
* with examination of bone densitometry
* with densitometric diagnosis of osteopenia in the first group, the second group for osteoporosis,
* willing to participate in the study

Exclusion Criteria:

* presence of severe scoliosis, ankylosing spondylitis, obesity
* presence of neurological diseases serious
The Effects of Seasonal Changes in Osteoporosis Treatment

There are few reports concerning to the seasonal variation of osteoporosis treatment. In this study, we plan to compare clinical efficacy and safety by seasons.

Vitamin D insufficiency is common in many countries. Vitamin D insufficiency is associated with osteoporosis and the responses to osteoporosis treatment. 25-hydroxyvitamin D (25OHD) is considered to be the best estimate of body stores of vitamin D and the seasonal variation of 25OHD is well known. But there are few reports concerning to the seasonal variation of osteoporosis treatment. In this study, we plan to compare clinical efficacy and safety by seasons in patients treated by raloxifene.

Eligibility Criteria:
Inclusion Criteria:

* Postmenopausal women

Exclusion Criteria:

* Patients who could not use SERM
Complementary Self-help Strategies for Patients With Post-COVID-19 Syndrome

Individuals affected by SARS-CoV-2 infection may subsequently be affected by the so-called post-COVID syndrome. The aim of the present study is to investigate the effects of a multimodal 10-week group program consisting of self-help strategies based on complementary medicine approaches of TEM (Traditional European Medicine), TCM (Traditional Chinese Medicine), and TIM (Traditional Indian Medicine) in addition to treatment as usual versus treatment as usual alone (no active study intervention/waiting list). Endpoints of the study include subjective quantitative and qualitative as well as objective (physician-reported) variables.


Eligibility Criteria:
Inclusion Criteria:

* Age of 18 years and older
* Confirmed COVID-19 diagnosis by: 1. polymerase chain reaction (PCR) test or 2. physician's letter/medical certificate/quarantine order due to ICD-10-GM U07.1 G or ICD-10-GM U09.9 G
* Sequelae symptoms, new symptoms/disabilities, or worsening of a pre-existing medical condition that occurred in the first 3 months after confirmed SARS-CoV-2 infection and persisted for more than 2 months
* At least 8 points (moderate symptom burden) out of a possible 32 points on the Somatic Symptom Scale-8 (SSS-8)

Exclusion Criteria:

* Patients who were treated with invasive ventilation during active SARS-CoV-2 infection
* Severe comorbid mental illness (e.g. addiction diagnosis, major depression) or other severe comorbid somatic illness (e.g. cancer without remission, severe pre-existing cardiovascular disease, insufficiency of other organs such as kidney or liver, acute febrile infection, other severe neurologic disease)
* Pregnancy or lactation
* Current pension application
* Simultaneous participation in other clinical/interventional trials